Reviews and Models
- Houghton, P.J., Adamson, P.C., Blaney, S., Fine, H.A., Gorlick, R., Haber, M., Helman, L., Hirschfeld, S., Hollingshead, M.G., Israel, M.A., Lock, R.B., Maris, J.M., Merlino, G., Patterson, W., Reynolds, C.P., Shannon, K., Yu, A., Yu, J., Smith, M.A. (2002). Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 8, 3646-57. PM:12473573
- Kang, M.H., Smith, M.A., Morton, C.L., Keshelava, N., Houghton, P.J., Reynolds, C.P. (2011). National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 56, 239-49. PM:20922763
- Houghton, P.J., Morton, C.L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E.A., Zhang, W., Lock, R., Carol, H., Tajbakhsh, M., Reynolds, C.P., Maris, J.M., Courtright, J., Keir, S.T., Friedman, H.S., Stopford, C., Zeidner, J., Wu, J., Liu, T., Billups, C.A., Khan, J., Ansher, S., Zhang, J., Smith, M.A. (2007). The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 49, 928-40. PM:17066459
- Whiteford, C.C., Bilke, S., Greer, B.T., Chen, Q., Braunschweig, T.A., Cenacchi, N., Wei, J.S., Smith, M.A., Houghton, P., Morton, C., Reynolds, C.P., Lock, R., Gorlick, R., Khanna, C., Thiele, C.J., Takikita, M., Catchpoole, D., Hewitt, S.M., Khan, J. (2007). Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 67, 32-40 PM:17210681
- Neale, G., Su, X., Morton, C.L., Phelps, D., Gorlick, R., Lock, R.B., Reynolds, C.P., Maris, J.M., Friedman, H.S., Dome, J., Khoury, J., Triche, T.J., Seeger, R.C., Gilbertson, R., Khan, J., Smith, M.A., Houghton, P.J. (2008). Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 14, 4572-83 PM:18628472
Papers on Testing of Specific Agents
- Carol, H., Lock, R., Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Reynolds, C.P., Maris, J.M., Keir, S.T., Billups, C.A., Smith, M.A. (2009). Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer 53, 1255-63 PM:19554570
- Carol, H., Morton, C.L., Gorlick, R., Kolb, E.A., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Billups, C., Smith, M.A., Houghton, P.J., Lock, R.B. (2010). Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer 55, 1329-37 PM:20740623
- Carol, H., Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Reynolds, C.P., Kang, M.H., Maris, J.M., Keir, S.T., Watkins, A., Smith, M.A., Lock, R.B. (2010). Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer 54, 707-15 PM:20017204
- Carol, H., Boehm, I., Reynolds, C.P., Kang, M.H., Maris, J.M., Morton, C.L., Gorlick, R., Kolb, E.A., Keir, S.T., Wu, J., Wozniak, A.E., Yang, Y., Manfredi, M., Ecsedy, J., Wang, J., Neale, G., Houghton, P.J., Smith, M.A., Lock, R.B. (2011). Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol 68, 1291-304 PM:21448591
- Carol, H., Reynolds, C.P., Kang, M.H., Keir, S.T., Maris, J.M., Gorlick, R., Kolb, E.A., Billups, C.A., Geier, B., Kurmasheva, R.T., Houghton, P.J., Smith, M.A., Lock, R.B. (2013). Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 60, 633-41 PM:22753001
- Carol, H., Gorlick, R., Kolb, E.A., Morton, C.L., Manesh, D.M., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Wozniak, A., Hickson, I., Lyalin, D., Kurmasheva, R.T., Houghton, P.J., Smith, M.A., Lock, R. (2014). Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61, 245-52 PM:24038993
- Carol, H., Maris, J.M., Kang, M.H., Reynolds, C.P., Kolb, E.A., Gorlick, R., Keir, S.T., Wu, J., Kurmasheva, R.T., Houghton, P.J., Smith, M.A., Lock, R.B. (2014). Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer , PM:24664981
- Gorlick, R., Kolb, E.A., Houghton, P.J., Morton, C.L., Phelps, D., Schaiquevich, P., Stewart, C., Keir, S.T., Lock, R., Carol, H., Reynolds, C.P., Maris, J.M., Wu, J., Smith, M.A. (2009). Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 53, 594-8 PM:19554571
- Gorlick, R., Maris, J.M., Houghton, P.J., Lock, R., Carol, H., Kurmasheva, R.T., Kolb, E.A., Keir, S.T., Reynolds, C.P., Kang, M.H., Billups, C.A., Smith, M.A. (2012). Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 59, 518-24 PM:22102563
- Gorlick, R., Kolb, E.A., Houghton, P.J., Morton, C.L., Neale, G., Keir, S.T., Carol, H., Lock, R., Phelps, D., Kang, M.H., Reynolds, C.P., Maris, J.M., Billups, C., Smith, M.A. (2012). Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer 59, 1266-74 PM:22315240
- Gorlick, R., Kolb, E.A., Keir, S.T., Maris, J.M., Reynolds, C.P., Kang, M.H., Carol, H., Lock, R., Billups, C.A., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2014). Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61, 158-64 PM:23956067
- Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Lock, R., Carol, H., Reynolds, C.P., Maris, J.M., Keir, S.T., Billups, C.A., Smith, M.A. (2008). Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 799-805 PM:17635004
- Houghton, P.J., Morton, C.L., Kolb, E.A., Lock, R., Carol, H., Reynolds, C.P., Keshelava, N., Maris, J.M., Keir, S.T., Wu, J., Smith, M.A. (2008). Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 37-45 PM:17420992
- Houghton, P.J., Morton, C.L., Gorlick, R., Lock, R.B., Carol, H., Reynolds, C.P., Kang, M.H., Maris, J.M., Keir, S.T., Kolb, E.A., Wu, J., Wozniak, A.W., Billups, C.A., Rubinstein, L., Smith, M.A. (2010). Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 9, 101-12 PM:20053767
- Houghton, P.J., Morton, C.L., Gorlick, R., Kolb, E.A., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Wu, J., Smith, M.A. (2010). Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 54, 921-6 PM:20166202
- Houghton, P.J., Morton, C.L., Kang, M., Reynolds, C.P., Billups, C.A., Favours, E., Payne-Turner, D., Tucker, C., Smith, M.A. (2010). Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatr Blood Cancer 55, 1224-6 PM:20979180
- Houghton, P.J., Lock, R., Carol, H., Morton, C.L., Phelps, D., Gorlick, R., Kolb, E.A., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Wozniak, A.W., Gu, Y., Wilson, W.R., Smith, M.A. (2011). Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer 57, 443-53 PM:21744473
- Houghton, P.J., Kang, M.H., Reynolds, C.P., Morton, C.L., Kolb, E.A., Gorlick, R., Keir, S.T., Carol, H., Lock, R., Maris, J.M., Billups, C.A., Smith, M.A. (2012). Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 58, 636-9 PM:21681929
- Houghton, P.J., Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Morton, C.L., Keir, S.T., Reynolds, C.P., Kang, M.H., Phelps, D., Maris, J.M., Billups, C., Smith, M.A. (2012). Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer 58, 191-9 PM:21337679
- Houghton, P.J., Lock, R., Carol, H., Morton, C.L., Gorlick, R., Anders, K.E., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Billups, C.A., Zhang, M.X., Madden, S.L., Teicher, B.A., Smith, M.A. (2012). Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer 58, 200-9 PM:21548007
- Kang, M.H., Reynolds, C.P., Houghton, P.J., Alexander, D., Morton, C.L., Kolb, E.A., Gorlick, R., Keir, S.T., Carol, H., Lock, R., Maris, J.M., Wozniak, A., Smith, M.A. (2012). Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 59, 185-8 PM:21538821
- Kang, M.H., Reynolds, C.P., Maris, J.M., Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Keir, S.T., Wu, J., Lyalin, D., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2014). Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer , PM:24623675
- Keir, S.T., Maris, J.M., Lock, R., Kolb, E.A., Gorlick, R., Carol, H., Morton, C.L., Reynolds, C.P., Kang, M.H., Watkins, A., Houghton, P.J., Smith, M.A. (2010). Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer 55, 1126-33 PM:20672370
- Keir, S.T., Maris, J.M., Reynolds, C.P., Kang, M.H., Kolb, E.A., Gorlick, R., Lock, R., Carol, H., Morton, C.L., Wu, J., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2013). Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer 60, 783-90 PM:23335050
- Keshelava, N., Houghton, P.J., Morton, C.L., Lock, R.B., Carol, H., Keir, S.T., Maris, J.M., Reynolds, C.P., Gorlick, R., Kolb, E.A., Wu, J., Smith, M.A. (2009). Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer 53, 505-8 PM:19418547
- Kolb, E.A., Gorlick, R., Houghton, P.J., Morton, C.L., Lock, R.B., Tajbakhsh, M., Reynolds, C.P., Maris, J.M., Keir, S.T., Billups, C.A., Smith, M.A. (2008). Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 1198-206 PM:17914733
- Kolb, E.A., Gorlick, R., Houghton, P.J., Morton, C.L., Lock, R., Carol, H., Reynolds, C.P., Maris, J.M., Keir, S.T., Billups, C.A., Smith, M.A. (2008). Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 1190-7 PM:18260118
- Kolb, E.A., Gorlick, R., Houghton, P.J., Morton, C.L., Neale, G., Keir, S.T., Carol, H., Lock, R., Phelps, D., Kang, M.H., Reynolds, C.P., Maris, J.M., Billups, C., Smith, M.A. (2010). Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 55, 668-77 PM:20806365
- Kolb, E.A., Gorlick, R., Lock, R., Carol, H., Morton, C.L., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Billups, C., Smith, M.A., Houghton, P.J. (2011). Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 56, 595-603 PM:21298745
- Kolb, E.A., Gorlick, R., Keir, S.T., Maris, J.M., Lock, R., Carol, H., Kurmasheva, R.T., Reynolds, C.P., Kang, M.H., Wu, J., Houghton, P.J., Smith, M.A. (2012). Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer 58, 815-8 PM:22052798
- Kolb, E.A., Gorlick, R., Reynolds, C.P., Kang, M.H., Carol, H., Lock, R., Keir, S.T., Maris, J.M., Billups, C.A., Desjardins, C., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2013). Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 60, 1325-32 PM:23553917
- Kurmasheva, R.T., Reynolds, C.P., Kang, M.H., Allievi, C., Houghton, P.J., Smith, M.A. (2014). Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. Pediatr Blood Cancer 61, 922-4 PM:24166988
- Lock, R., Carol, H., Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Reynolds, C.P., Maris, J.M., Keir, S.T., Wu, J., Smith, M.A. (2008). Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 1181-9 PM:18085673
- Lock, R.B., Carol, H., Morton, C.L., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Wozniak, A.W., Gorlick, R., Kolb, E.A., Houghton, P.J., Smith, M.A. (2012). Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer 58, 916-23 PM:21584937
- Lock, R.B., Carol, H., Maris, J.M., Kang, M.H., Reynolds, C.P., Kolb, E.A., Gorlick, R., Keir, S.T., Billups, C.A., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2013). Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 60, E42-E45 PM:23303741
- Maris, J.M., Courtright, J., Houghton, P.J., Morton, C.L., Kolb, E.A., Lock, R., Tajbakhsh, M., Reynolds, C.P., Keir, S.T., Wu, J., Smith, M.A. (2008). Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 51, 42-8 PM:18293383
- Maris, J.M., Courtright, J., Houghton, P.J., Morton, C.L., Gorlick, R., Kolb, E.A., Lock, R., Tajbakhsh, M., Reynolds, C.P., Keir, S.T., Wu, J., Smith, M.A. (2008). Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 581-7 PM:17457854
- Maris, J.M., Morton, C.L., Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Keir, S.T., Reynolds, C.P., Kang, M.H., Wu, J., Smith, M.A., Houghton, P.J. (2010). Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 55, 26-34 PM:20108338
- Morton, C.L., Houghton, P.J., Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Billups, C., Smith, M.A. (2009). Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr Blood Cancer 53, 509-12 PM:19418543
- Morton, C.L., Houghton, P.J., Kolb, E.A., Gorlick, R., Reynolds, C.P., Kang, M.H., Maris, J.M., Keir, S.T., Wu, J., Smith, M.A. (2010). Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer 55, 295-303 PM:20582972
- Reynolds, C.P., Kang, M.H., Keir, S.T., Gorlick, R., Kolb, E.A., Lock, R., Maris, J.M., Carol, H., Morton, C.L., Billups, C.A., Smith, M.A., Houghton, P.J. (2011). Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatr Blood Cancer 57, 606-11 PM:21360651
- Reynolds, C.P., Kang, M.H., Carol, H., Lock, R., Gorlick, R., Kolb, E.A., Kurmasheva, R.T., Keir, S.T., Maris, J.M., Billups, C.A., Houghton, P.J., Smith, M.A. (2013). Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer 60, 791-8 PM:23002019
- Smith, M.A., Morton, C.L., Phelps, D.A., Kolb, E.A., Lock, R., Carol, H., Reynolds, C.P., Maris, J.M., Keir, S.T., Wu, J., Houghton, P.J. (2008). Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer 51, 34-41 PM:18260120
- Smith, M.A., Morton, C.L., Kolb, E.A., Gorlick, R., Keir, S.T., Carol, H., Lock, R., Kang, M.H., Reynolds, C.P., Maris, J.M., Watkins, A.E., Houghton, P.J. (2010). Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer 54, 307-10 PM:19856388
- Smith, M.A., Maris, J.M., Lock, R., Kolb, E.A., Gorlick, R., Keir, S.T., Carol, H., Morton, C.L., Reynolds, C.P., Kang, M.H., Houghton, P.J. (2011). Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer 57, 268-74 PM:21360650
- Smith, M.A., Kang, M.H., Reynolds, C.P., Kurmasheva, R.T., Alexander, D., Billups, C.A., Toretsky, J.A., Houghton, P.J. (2012). Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma. Pediatr Blood Cancer 59, 753-5 PM:22315235
- Smith, M.A., Maris, J.M., Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Keir, S.T., Reynolds, C.P., Kang, M.H., Morton, C.L., Wu, J., Smith, P.G., Yu, J., Houghton, P.J. (2012). Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer 59, 246-53 PM:22012946
- Smith, M.A., Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Maris, J.M., Keir, S.T., Morton, C.L., Reynolds, C.P., Kang, M.H., Arts, J., Bashir, T., Janicot, M., Kurmasheva, R.T., Houghton, P.J. (2012). Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer 59, 329-32 PM:21922647
- Tajbakhsh, M., Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Maris, J.M., Keir, S.T., Wu, J., Reynolds, C.P., Smith, M.A., Lock, R.B. (2008). Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 992-1000 PM:17554786
- Wood, A.C., Maris, J.M., Gorlick, R., Kolb, E.A., Keir, S.T., Reynolds, C.P., Kang, M.H., Wu, J., Kurmasheva, R.T., Whiteman, K., Houghton, P.J., Smith, M.A. (2013). Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer 60, 1860-7 PM:23798344